Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension

被引:119
作者
Stenmark, Kurt R. [1 ,2 ]
Frid, Maria G. [1 ,2 ]
Graham, Brian B. [3 ]
Tuder, Rubin M. [3 ]
机构
[1] Univ Colorado, Cardiovasc Pulm Res Labs, Dept Pediat, Anschutz Med Campus,12700 E 19th Ave,RC2,B131, Aurora, CO 80045 USA
[2] Univ Colorado, Cardiovasc Pulm Res Labs, Dept Med, Anschutz Med Campus,12700 E 19th Ave,RC2,B131, Aurora, CO 80045 USA
[3] Univ Colorado, Pulm & Crit Care Med, Dept Med, Anschutz Med Campus,12700 E 19th Ave,RC2,B131, Aurora, CO 80045 USA
基金
美国国家卫生研究院;
关键词
Progenitor cells; Endothelial mesenchymal transition; Inflammation; Metabolism; Senescence; TO-MESENCHYMAL TRANSITION; PROGENITOR CELLS; ARTERIAL-HYPERTENSION; MOLECULAR-MECHANISMS; PLEXIFORM LESIONS; ENHANCED GROWTH; GENE-EXPRESSION; CD133(+) CELLS; MESSENGER-RNA; IN-VITRO;
D O I
10.1093/cvr/cvy004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) is the end result of interaction between pulmonary vascular tone and a complex series of cellular and molecular events termed 'vascular remodelling'. The remodelling process, which can involve the entirety of pulmonary arterial vasculature, almost universally involves medial thickening, driven by increased numbers and hypertrophy of its principal cellular constituent, smooth muscle cells (SMCs). It is noted, however that SMCs comprise heterogeneous populations of cells, which can exhibit markedly different proliferative, inflammatory, and extracellular matrix production changes during remodelling. We further consider that these functional changes in SMCs of different phenotype and their role in PH are dynamic and may undergo significant changes over time (which we will refer to as cellular plasticity); no single property can account for the complexity of the contribution of SMC to pulmonary vascular remodelling. Thus, the approaches used to pharmacologically manipulate PH by targeting the SMC phenotype(s) must take into account processes that underlie dominant phenotypes that drive the disease. We present evidence for time- and location-specific changes in SMC proliferation in various animal models of PH; we highlight the transient nature (rather than continuous) of SMC proliferation, emphasizing that the heterogenic SMC populations that reside in different locations along the pulmonary vascular tree exhibit distinct responses to the stresses associated with the development of PH. We also consider that cells that have often been termed 'SMCs' may arise from many origins, including endothelial cells, fibroblasts and resident or circulating progenitors, and thus may contribute via distinct signalling pathways to the remodelling process. Ultimately, PH is characterized by long-lived, apoptosis-resistant SMC. In line with this key pathogenic characteristic, we address the acquisition of a pro-inflammatory phenotype by SMC that is essential to the development of PH. We present evidence that metabolic alterations akin to those observed in cancer cells (cytoplasmic and mitochondrial) directly contribute to the phenotype of the SM and SM-like cells involved in PH. Finally, we raise the possibility that SMCs transition from a proliferative to a senescent, pro-inflammatory and metabolically active phenotype over time.
引用
收藏
页码:551 / 564
页数:14
相关论文
共 140 条
[1]   Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension [J].
Abe, Kohtaro ;
Toba, Michie ;
Alzoubi, Abdallah ;
Ito, Masako ;
Fagan, Karen A. ;
Cool, Carlyne D. ;
Voelkel, Norbert F. ;
McMurtry, Ivan F. ;
Oka, Masahiko .
CIRCULATION, 2010, 121 (25) :2747-2754
[2]   Short telomeres are a risk factor for idiopathic pulmonary fibrosis [J].
Alder, Jonathan K. ;
Chen, Julian J. -L. ;
Lancaster, Lisa ;
Danoff, Sonye ;
Su, Shu-Chih ;
Cogan, Joy D. ;
Vulto, Irma ;
Xie, Mingyi ;
Qi, Xiaodong ;
Tuder, Rubin M. ;
Phillips, John A., III ;
Lansdorp, Peter M. ;
Loyd, James E. ;
Armanios, Mary Y. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (35) :13051-13056
[3]  
ALEXANDER AF, 1963, AM J VET RES, V24, P1098
[4]   CCR5 as a Treatment Target in Pulmonary Arterial Hypertension [J].
Amsellem, Valerie ;
Lipskaia, Larissa ;
Abid, Shariq ;
Poupel, Lucie ;
Houssaini, Amal ;
Quarck, Rozenn ;
Marcos, Elisabeth ;
Mouraret, Nathalie ;
Parpaleix, Aurelien ;
Bobe, Regis ;
Gary-Bobo, Guillaume ;
Saker, Mirna ;
Dubois-Rande, Jean-Luc ;
Gladwin, Mark T. ;
Norris, Karen A. ;
Delcroix, Marion ;
Combadiere, Christophe ;
Adnot, Serge .
CIRCULATION, 2014, 130 (11) :880-+
[5]  
Aoshiba Kazutetsu, 2009, Proc Am Thorac Soc, V6, P596, DOI 10.1513/pats.200904-017RM
[6]   Mitochondrial metabolism, redox signaling, and fusion:: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer [J].
Archer, Stephen L. ;
Gomberg-Maitland, Mardi ;
Maitland, Michael L. ;
Rich, Stuart ;
Garcia, Joe G. N. ;
Weir, E. Kenneth .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2008, 294 (02) :H570-H578
[7]   Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension [J].
Arciniegas, Enrique ;
Frid, Maria G. ;
Douglas, Ivor S. ;
Stenmark, Kurt R. .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2007, 293 (01) :L1-L8
[8]  
Armanios MY, 2007, N ENGL J MED, V356
[9]   Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension [J].
Asosingh, Kewal ;
Farha, Samar ;
Lichtin, Alan ;
Graham, Brian ;
George, Deepa ;
Aldred, Micheala ;
Hazen, Stanley L. ;
Loyd, James ;
Tuder, Rubin ;
Erzurum, Serpil C. .
BLOOD, 2012, 120 (06) :1218-1227
[10]   ET-1 receptor gene expression and distribution in L1 and L2 cells from hypertensive sheep pulmonary artery [J].
Balyakina, EV ;
Chen, DH ;
Lawrence, ML ;
Manning, S ;
Parker, RE ;
Shappell, SB ;
Meyrick, B .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2002, 283 (01) :L42-L51